Atopic Dermatitis

Ruxolitinib cream, to be sold under the name Opzelura, is the first topical Janus kinase inhibitor cream for the treatment of atopic dermatitis.

A review of therapies for atopic dermatitis (AD) found adequate net health benefit for new treatments. However, safety remains a concern for the Janus kinase (JAK) inhibitors.

Researchers assess mortality rates among those with just asthma, just atopic dermatitis, and individuals with both conditions in Denmark.

Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier.

Patients had atopic dermatitis for nearly 10 years before starting the biologic therapy.

Children who were born to women with a history of asthma had a 45% increased risk of being diagnosed with atopic dermatitis/eczema up to age 8 years.

A survey in France found that systemic medications are used by only half of dermatologists in treating atopic dermatitis, with methotrexate used more than cyclosporine.

There is no consistent evidence showing clear benefit of various nutritional factors on the risk of atopic dermatitis.

Despite the level of disease severity of atopic dermatitis, children with the condition usually have at least 1 other inflammatory or atopic comorbidity, according to new study results.

Ohio dermatologist Matthew J. Zirwas, MD, offers his view on what step therapy would look like in patients with atopic dermatitis.

A new study of dupilumab indicates that the drug is a safe and effective treatment for atopic dermatitis (AD) in elderly patients, with efficacy comparable to that seen in younger patients.

Patients often ask how long they have to stay on biologic treatment for atopic dermatitis (AD), but there is a risk if therapy is stopped, says Matthew J. Zirwas, MD, a dermatologist in Ohio.